DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Histiocytosis — screening already-approved drugs against its 27-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHistiocytosis maps to a 27-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for histiocytosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nucleoporin 43 (NUP43) — NUP43 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4I79 · 1.75 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
A 1996 case report describes a 50-year-old woman with more than 100 generalised reddish-brown papules over six months. The infiltrate was positive for factor XIIIa, HAM56, KiM1p, and S100 protein, but lacked Birbeck granules on ultrastructure. The authors propose that indeterminate cell histiocytosis is a distinct entity with immunophenotypic features of both X- and non-X histiocytoses, and that generalised eruptive histiocytoma may represent an early indeterminate stage of several non-X syndromes.
A 1971 review of 129 cases of histiocytosis X discusses the natural history and prognostic factors, but provides no quantitative treatment outcomes. A 1979 prospective trial from the Childrens Cancer Study Group tested chlorambucil at 5 mg/m²/day in 26 evaluable patients, 57% of whom were under two years old. There were three complete and four partial responses to chlorambucil, a 26.9% response rate. Sixteen patients who did not respond then received a four-drug combination of prednisone, vinblastine, cyclophosphamide, and methotrexate, yielding three complete and two partial responses, a 33% response rate. The authors state these results were inferior to previously reported outcomes for either single agents or combined therapy in histiocytosis X.
A 2005 preface notes that the book is intended as a comprehensive reference for clinicians and researchers, and acknowledges that patients often encounter caregivers who say they know nothing about histiocytosis and are uncomfortable managing it.
No controlled trial has established a standard therapy for histiocytosis. The 1979 chlorambucil trial was small and its results disappointing compared to earlier reports. What is missing is adequate funding for prospective, randomised trials with clearly defined risk stratification, and a coordinated effort to recruit sufficient numbers of patients across the rare histiocytic disorders.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 1996 · 72 citations
Indeterminate cell histiocytosis-a clinicopathological entity with features of both X- and non-X histiocytosis
AbstractAn otherwise healthy 50-year-old woman presented with a 6-month history of having developed more than 100 generalized, non-confluent, reddish-brown, partially yellow-coloured papules. A non-epidemotropic, monomorphous infiltrate of vacuolated mononuclear, and occasionally multinuclear, histiocytes, positive for factor XIIIa and macrophage markers HAM56 and KiM1p, was consistent with the clinical impression of generalized eruptive histiocytomas. However, the additional reactivity for S100 protein, in the absence of features of histiocytosis X, suggested a diagnosis of indeterminate cell histiocytosis (ICH). Further immunohistochemical studies, performed on snap-frozen material, characterized the lesions as being diffusely positive with LN3 (HLA-DR), Leu4 (CD3) and Leu3 (CD4), the infiltrate in the upper dermis as reactive for OKT6 (CD1) and IOT6c (CD1c), and the infiltrate in the lower dermis as reactive for a variety of macrophage markers. Ultrastructural studies showed various non-specific features of histocytic disorders, but no Birbeck granules. Our findings confirm those of previous reports suggesting that ICH is a distinct histiocytic entity, characterized by immunophenotypic features of both X- and non-X histiocytoses. Generalized eruptive histiocytoma seems to be an early indeterminate stage of various non-X histiocytic syndromes including ICH, multicentric reticulohistiocytosis, xanthogranuloma and xanthoma disseminatum. The distribution pattern of the various X/non-X histiocytic markers suggests dermal arrest of antigen-presenting cells during their physiological trafficking from the skin to the lymph nodes.
Journal of Bone and Joint Surgery - British Volume · 1971 · 53 citations
HISTIOCYTOSIS X
Abstract1. The clinical, histological and radiological findings in 129 cases of histiocytosis X have been reviewed and the natural history of the disease is discussed. 2. Certain clinical and histological factors emerge as having prognostic significance. 3. The treatment in thirty-four personally reviewed cases is discussed and some suggestions are made as to the treatment of particular types of case.
Medical and Pediatric Oncology · 1977 · 38 citations
Combination Chemotherapy in Histiocytosis X
AbstractTwenty-five children with generalized histiocytosis X were treated with a combination of cyclophosphamide, vinblastine, and prednisone: 8 patients experienced complete response, 8 partial response, 2 imporvement, and 7 no response. Response rates for children over 1 year of age were higher than those reported for single agents. Twelve children are now off therapy with no evidence of disease for 10--50 months. Very poor response rates and high toxicity were seen in children less than 1 year of age. The two infants who eventually achieved CR did so by other therapies. Further trials in combination chemotherapy must weight possible long-term effects of such therapy against the prospect of more rapid disease control.
Medical and Pediatric Oncology · 1979 · 20 citations
Histiocytosis X: Clinical trial of chlorambucil: A report from childrens cancer study group
AbstractA prospective study for histiocytosis X was designed to determine whether "good risk" patients, ie, those without evidence of dysfunction of liver, lung, or hemopoietic system, would respond to single agent therapy; in this case chlorambucil (CMB) used in a dose of 5 mgm/m2/day. If there was no response after an adequate trial period, treatment was initiated with four drugs using a combination of prednisone, vinblastine, cyclophosphamide and methotrexate. There were 26 evaluable patients, 57% of whom were less than two years of age at onset of therapy. There were three complete and four partial responses to CMB for a response rate of 26.9%. Sixteen patients received an adequate trial of four-drug therapy with three complete and two partial responses for a response rate of 33%. These responses were inferior to those previously reported for either single agents or combined therapy in histiocytosis X.
Cambridge University Press eBooks · 2005 · 0 citations
Preface
AbstractThis book, the only current comprehensive text on the histiocytic disorders, is intended to be a useful source of information for all those who care for patients with one of the histiocytoses, for clinicians with primary responsibility for patient management, physicians concerned with laboratory medicine, and all who are involved with research in the field. Furthermore, patients with histiocytosis and/or their families may well find it useful to have the book as a standard reference for themselves and for every caregiver who tells them that histiocytosis is rare and that they know nothing about the condition and do not feel comfortable managing it.
Janus Kinase Inhibitor Treatment Outcomes in Cutaneous Histiocytosis: A Systematic Review
AbstractCutaneous histiocytoses represents a group of rare skin disease characterized by small brown or erythematous papules, with overlying nodules and crusting. Refractory cases are often treated with immunosuppressive therapy, however many cases still lead to poor treatment outcomes. Here, we review the outcomes of Janus Kinase inhibitors (JAKi), a novel therapy in cutaneous histiocytosis refractory to traditional systemic therapies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
